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Abstract
Many aspects of development, tumor growth and metastasis depend upon the provision of an adequate vasculature. This
can be a result of regulated angiogenesis, recruitment of circulating endothelial progenitors and/or vascular trans-
differentiation. The present study demonstrates that treatment of SKBR-3 breast cancer cells with retinoic acid (RA), an
important regulator of embryogenesis, cancer and other diseases, stimulates the formation of networks in Matrigel. RA-
treatment of SKBR-3 cells co-cultured with human umbilical vein endothelial cells resulted in the formation of mixed
structures. RA induces expression of many endothelial genes including vascular endothelial (VE) cadherin. VE-cadherin was
also induced by RA in a number of other breast cancer cells. We show that RA-induced VE-cadherin is responsible for the RA-
induced morphological changes. RA rapidly induced the expression of Sox-9 and ER81, which in turn form a complex on the
VE-cadherin promoter and are required to mediate the transcriptional regulation of VE-cadherin by RA. These data indicate
that RA may promote the expression of endothelial genes resulting in endothelial-like differentiation, or provide a
mechanism whereby circulating endothelial progenitor cells could be incorporated into a growing organ or tumor.
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Introduction
Organogenesis during embryonic development and tumor
growth are dependent on adequate vasculature. For example a
breast tumor that is unable to induce angiogenesis fails to reach a
size greater than 4 mm and is incapable of distant metastasis.
Metastatic lesions are often the source of cancer symptoms and the
primary cause of death in cancer patients. Thus, the degree of
vascularization of the tumor is one of the most important negative
prognostic parameters in breast cancer.
Illustrating how a tumor induces new vasculature is, therefore, a
crucial step to understand molecular nature of tumor progression.
The classic paradigm of the angiogenic switch states that, as the
tumor expands, central necrosis occurs due to hypoxia and
nutrient deprivation[1]. This leads to the production of angiogenic
factors such as VEGF and the recruitment of endothelial cells from
neighboring blood vessels or circulating progenitors[2]. An
alternative concept of tumor angiogenesis has been proposed in
which some tumor cells trans-differentiate into endothelial cells
and give rise to patterned spheroidal tumor clusters containing
channel-like spaces between them capable of mimicking the
circulatory system [3]. This phenomenon, termed as ‘‘vasculogenic
mimicry’’, is highly predicative of clinical outcome in patients with
aggressive melanoma. Vasculogenic mimicry also occurs in other
tumor types including breast cancer [4–7]. In the breast cancer
model, blood flows between tumor cell-lined vascular spaces and
endothelium-lined and/or mature vasculature. However, detailed
molecular mechanisms underlying vasculogenic mimicry still
remain to be elucidated, and it is not known if any treatment
regimens can regulate this process.
Retinoids, natural or synthetic vitamin A analogues, have been
used in anti-cancer therapy for many years. RA exhibits
differentiation and cell cycle arrest-dependent growth inhibition
properties in many cells and tissues. Many clinical and
experimental model studies have shown that retinoids and their
derivatives are effective in prevention and treatment of breast
cancer [8–10]. On the other hand, treatment of primary lung
cancer with b-carotene, the most important dietary precursor of
vitamin A, induced an even higher incidence of lung cancer
[11,12]. Fenretinide, a vitamin A analogue, appears to reduce the
risk of second breast cancers in premenopausal women, but
increases risk in postmenopausal women [13]. These studies imply
that retinoids may be effective in a preventative setting, but may
actually have a negative effect after tumor initiation and during
progression, particularly in estrogen-depleted circumstances. As
some tumor cells may harbor a pluripotent stem cell phenotype,
retinoid-induced ‘‘differentiation’’ during carcinogenesis could
result in either a negative outcome (e.g. vascular or mesenchymal
differentiation) or a positive one (e.g. mammary epithelial
differentiation). In other words, retinoid-dependent ‘‘differentia-
tion’’ may be responsible both for its failure as a treatment in
certain circumstances as well as its side effects, due to its action on
non-tumor cells. In the present study, we report that 9-cis-RA
induced endothelial-like differentiation in the estrogen receptor
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array analysis, we found that 9-cis-RA treatment resulted in an
endothelial-like genetic program and robustly induced VE-
cadherin. 9-cis-RA treatment induced VE-cadherin in four other
breast cancer cells. We also show that Sox-9 and the Ets-1 family
member ER81 are required for the transcriptional regulation of
VE-cadherin by 9-cis-RA.
Materials and Methods
Materials and Reagents
9-cis-RA was obtained from Sigma-Aldrich (Germany), mouse
anti-VE-cadherin was from Immunotech (France) and R&D
systems (Minneapolis, MN), goat anti-VE-cadherin were from
Santa Cruz Biotechnology (Santa Cruz, CA), rabbit anti-Sox-9
was from Chemicon (Temecula, CA), anti-myc was from
Invitrogen (Carlsbad, CA), anti-FLAG (M2) was from Sigma,
anti-GAPDH was from Research Diagnostics Inc (Flanders, NJ).
Small interference RNA (siRNA) reagent (SMART pool) for
human VE-cadherin was purchased from Dharmacon (Lafayette,
CO). As a control siRNA, Luc siRNA was used (CGUACGCG-
GAAUACUUCGA). Plasmid DNA encoding wild type (WT) Sox-
9 and dominant negative (DN) form of Sox-9 (lacking the C-
terminal trans-activation domain) were kindly provided by Dr.
Ve ´ronique Lefebvre (Cleveland Clinic Foundation, Cleveland,
OH). 66Myc ER81
(2–477) and 66Myc-ER81
(249–477) were kindly
provided by Dr. Ralf Janknecht (Mayo Clinic, Rochester, MN).
Human VE-cadherin cDNA was kindly provided by Dr. William
A. Miller (Cornell University, New York, NY).
Cell Culture and Transfection
Early passage (,passage 30) SKBR-3 cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) in 5% CO2 incubator at 37uC.
All transient transfection experiments of plasmid DNA and siRNA
were performed with Amaxa electroporation system (Amaxa, Inc,
Gaithersburg, MD) according to the manufacturer’s protocol.
Electron Microscopy
Following 48 h of RA treatment 80% confluent SkBr3 cells
were rinsed in PBS and trypsinized for 30 seconds to detach cell
sheets from the plate but maintain cell-cell contacts. 10% FBS was
added to stop the action of the trypsin. Cells were gently
centrifuged (3006g) for 2 minutes, the medium decanted and
one ml of warm 2% liquid agar was added to the cell pellet and
allowed to solidify (5 minutes). The cells were fixed in 2%
glutataldehyde for three hours at room temperature rinsed in PBS
and post fixed in 2% Osmium Tetroxide overnight at 4uC. The
pellets were rinsed again in PBS, dehydrated and embedded in
epon 812. 600 angstrom sections were cut and viewed on a
Siemens transmission electron microscope.
Matrigel Assay
Each well of a 12-well glass-bottom dish (MatTek, Ashland,
MA) was coated with 100 mL of Matrigel (BD Biosciences, San
Jose, CA) and incubated 15 min at 37uC. SKBR-3 cells (15,000
cells/100 ml medium) were gently plated on top of the Matrigel
layer directly and further incubated 30 min at 37uC. One milliliter
of growth medium was added along with either ethanol control or
the appropriate concentration of 9-cis-RA. Cells were maintained
at 37uC in a 5% CO2 incubator, and the media and 9-cis-RA were
replenished every 48 h. On day 11, cells were stained with 1 mg/
ml of Calcein AM (Invitrogen) for 30 min at 37uC before
visualization.
Network Formation and Mixed Vessel Assay
SKBR-3 cells were pre-treated for 24 hours with ethanol
control or 10
27M9 - cis-retinoic acid. The SKBR-3 cells were
trypsinized, and cell suspended to 10
6cells/ml. Glass-bottom
dishes (Mattek) were plated with 125 ul of Matrigel (BD
Biosciences) and allowed to polymerize for 30 min in the
incubator. 100 ul of cell suspension was plated on top of the
Matrigel layer and incubated at 37uC for 30 minutes. 1 mL of
DMEM (Invitrogen) or EGM (Cambrex) supplemented with
control or 10
27M RA was added to the appropriate wells. For
mixed vessel assays SKBR-3 cells and HUVEC cells were treated
with 15 mM CFMDA (Invitrogen) or 15 mM CMTPX (Invitro-
gen), respectively for 30 minutes at 37uC. The media was changed
and cells were incubated for an additional 30 minutes at 37uC.
The SKBR-3 cells and HUVECs were trypsinized, and suspended
to 5610
5cells/ml. 50 ul of HUVECs were mixed with an equal
volume of treated or untreated SKBR-3 cells. 100 ul of each
suspension was plated on top of the Matrigel layer and incubated
at 37uC for 30 minutes. 1 mL of DMEM (Invitrogen) or EGM
(Cambrex) supplemented with control or 10
27M RA was added to
the appropriate wells. The networks and mixed vessels were
imaged using an Olympus IX71 Inverted Fluorescent Microscope.
Microarray Analysis
SKBR-3 cells were incubated in the presence or absence of 9-
cis-RA (1 mM) for 48 h. Total RNA was isolated using Trizol
(Invitrogen) combined with RNAeasy (Qiagen, Valencia, CA) and
was amplified according to the Affymetrix protocol (GeneChip
Eukaryotic Small Sample target labeling Assay Version II)
modified so that the ethanol precipitation cDNA cleanup step
was substituted by Qiaquick PCR purification kit (Qiagen). Biotin-
11-CTP and biotin-16-UTP (Enzo Diagnostics, Farmingdale, NY)
was incorporated during in vitro transcription and 20 ug of the
biotinylated cRNA product was fragmented at 94uC for 25 min.
Treated and untreated samples were amplified, labeled, fragment-
ed and hybridized in the same run. Hybridizations to Affymetrix
HG-U133A GeneChips were performed at 45uC for 16 h followed
by staining and washing as described in the manufacturer’s
instructions. The processed chips were then scanned using an
Affimatrix GeneArray scanner. Grid alignment and raw data
generation were performed using Affymetrix GeneChip 5.0
Software. For quality control, oligo B2 was hybridized to the chip
and the checkerboard pattern in each corner of the chip analyzed.
BioB, bioC and bioD probes are added to each sample to
standardize hybridization, staining and washing procedures. Raw
expression values representing the average difference in hybrid-
ization intensity between oligonucleotides containing single base
pair mismatches, was measured.
Real-time quantitative PCR
Relative quantification was used to evaluate the raw data
obtained from real-time PCR (7900 HT real time PCR system, 96
well format, Applied Biosystems, Foster City, CA). All standards
and unknowns were performed in triplicate. The average value of
the triplicate readings for each unknown was then divided by the
corresponding value for 18S ribosomal RNA to normalize the
data. After normalization, the value obtained for the treated
unknown was divided by the value obtained for the corresponding
untreated sample. The final value obtained was a measure of the
fold change in gene expression for the particular genes of interest
between the treated sample and the untreated sample. For all
analyses a p-value of ,0.05 was considered to be statistically
significant.
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Total RNA was isolated with Trizol reagent (Invitrogen). cDNA
was prepared by first strand cDNA synthesis kit (Invitrogen). PCR
primer sequences were as followings. ER81-F (59-CCAAACT-
CAACTCATACACCGAAACC-39), ER81-R (59-TGGCTCTTG-
TTTGATGTCTCC-39), E-selectin-F (59-CCTACAAGTCCT-
CTTGTGCC-39), E-selectin-R (59-GCTAATGTCAGGAGGGA-
GAG-39), cyclooxygenase (Cox)-1-F (59-AGGAGTACAGCTAC-
GAGCAG-39), Cox-1-R (59-CCTCAGAGCTCTGTGGATGG-
39), b-actin-F (59-TGACGGGGTCACCCACACTGTGCCCAT-
CTA-39), b-actin-R (59-CTAGAAGCATTTG CGGTGGAC-
GATGGAGGG-39).
Immunocytochemistry
SKBR-3 cells seeded on glass cover slips in DMEM medium
(10
5 cells/well in 24 well plate) were treated with either 9-cis-RA
(0.1 or 1 mM) or control medium and incubated for indicated
times. Then cells were fixed with cold methanol at 220uC for
20 min for VE-cadherin staining, or with freshly prepared 3.7%
formaldehyde for 15 min at room temperature (RT) followed by
permeablization with 0.1% Triton X-100/PBS for 5 min for
phalloidin staining. After blocking with 5% BSA/PBS for 1 h at
RT, fixed cells were incubated overnight at 4uC with VE-cadherin
antibody diluted 1:1000 (mouse anti-VE-cadherin) or 1:200 (goat
anti-VE-cadherin) in 2% BSA/PBS, followed by incubation with
Alexa Fluor 488-labeled anti-mouse IgG (1:1000, Invitrogen) or
anti-goat IgG (1:1000, Invitrogen) for 30 min at RT. For
phalloidin staining, Alexa Fluor 488 or 568-labeled phalloidin
was used (1:2000, Invitrogen). For nuclear staining, 49,6 -
Diamidine-29-phenylindole dihydrochloride (DAPI) was used.
Nikon E600 Fluorescence Microscope with Hamamatsu Orca-
100 and 206,4 0 6,6 0 6objective lens and MetaMorph (version
6.1.5) imaging analysis software (Universal Imaging Corp.) were
used to detect fluorescence. Images were processed with Adobe
Photoshop Elements 2.0 (Adobe Inc., San Jose, CA).
Immunoblotting
Eighty-90% confluent SKBR-3 cells were incubated with
DMEM in the presence or absence of 9-cis-RA for indicated
times. Cells were rinsed twice with PBS and lysed with buffer
containing 1% NP-40, 1% sodium deoxycholate, 0.1% SDS,
150 mM NaCl, 10 mM sodium phosphate, pH 7.2 and complete
mini protease inhibitors (Roche Applied Science, Indianapolis,
IN). Cell lysates were clarified by centrifugation at 14,000 rpm for
10 min at 4uC. Protein concentration was determined with a Bio-
Rad DC reagent (Bio-Rad, Hercules, CA). After SDS-PAGE,
proteins were transferred to Immobilon P (Millipore, Billerica,
MA). Membranes were blocked with 5% milk in Tris-Buffered
Saline containing 0.1% Tween-20, and incubated with primary
antibody overnight at 4uC and subsequently with HRP-labeled
secondary antibody. Proteins were visualized with ECL reagents
(Amersham Biosciences, Piscataway, NJ) or SuperSignal West
Femto (Pierce biotechnology Inc., Rockford, IL), using X-ray films
(Denville Scientific Inc., Metuchen, NJ).
Electrophoretic Mobility Shift Assays (EMSA)
Nuclear extract preparation. SKBR-3 cells were incubated
in the presence or absence of 9-cis-RA (1 mM) for 48 h, and
washed twice with PBS, harvested with ice-cold PBS containing
protease/phosphatase inhibitors (1 mM sodium orthovanadate,
10 mM b-glycerophosphate, 1 mM DTT [Dithiothreitol], 1 mM
PMSF [Phenylmethylsulfonyl Fluoride]). Cells were spun down at
1,200 rpm for 5 min at 4uC, and pellets were resuspended with
ice-cold Buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA) containing protease/phosphatase
inhibitors. After incubation on ice for 10–15 min, Triton-X 100
was added (0.5%), and cells were vortexed for 10 sec, spun down
at 3,000 rpm for 3 min at RT, and supernatant (cytoplasmic
extract) was removed. The pellet was re-suspended with Buffer C
(20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM
EGTA) containing protease/phosphatase inhibitors, vortexed,
incubated on ice for 15 min, and spun down for 5 min at
12,000 rpm at 4uC. The supernatant was used as nuclear extract.
32P-DNA oligonucleotide probes. Sense and antisense
strand oligo DNA were separately dissolved in TE (pH 8.0).
Denaturing and annealing were performed in annealing buffer
(10 mM Tris-HCl pH 7,5, 50 mM NaCl, 1 mM EDTA). 59-end
phosphorylation of the annealed DNA was performed using T4
polynucleotide kinase (New England BioLabs, Beverly, MA) and
c-
32P-ATP (Amersham) at 37uC for 10 min. Labeled probes were
purified using G-25 spin columns.
Binding reaction and electrophoresis. Nuclear extract
(2 mg) was incubated with 56 binding buffer (Promega, Cat#
E3581) for 10–15 min at RT. Ten fmol of DNA probe was added
and the mixture was incubated for 15–20 min at RT. In some
experiments, antibody was added to the mixture, and further
incubated for 10 min at RT. Loading buffer (3.3% Ficoll 400,
1.67% Glycerol, 0.041% Orange G) was added to each sample,
and electrophoresed with 6% TBE/polyacrylamide gel and 0.56
TBE buffer. Gels were fixed with 40% methanol and 10% acetic
acid for 15 min at RT, and dried under vacuum for 2 h at 80uC.
Gels were scanned by a Molecular Dynamics 445 SI
Phosphorimager, and analyzed with ImageQuaNT software
(Amersham Biosciences, Piscataway, NJ).
The following probes were used:
Antibody Neutralization
Mouse monoclonal antibody raised against an antigen encoding
the extracellular domain of human VE-cadherin (amino acids 48–
593) was used as a neutralizing antibody (R&D systems). Cells
were pre-treated with either the VE-cadherin antibody or with
control mouse IgG (50 mg/ml) for 6 h, followed by 48 h
incubation in the presence or absence of 9-cis-RA (0.1 mM).
Results
9-cis-RA induced an endothelial-like morphological
change in SKBR-3 cells
SKBR-3 cells treated with 9-cis-RA for 48 h became flattened
and/or extended (Fig. 1A) in compared with control. In many
cells, actin-lined lumen-like structures as well as cytoplasmic
extensions, which resembled channels, sinuses, and vessel-like
structures reminiscent of differentiated endothelial cell cultures
were observed (Fig. 1A, right). Electron microscopy further
revealed formation of cell-cell junctions in the presence of 9-cis-
RA, indicating formation of rudimentary lumen structure in
WT : CAAAGGAACAATAACAGGAAACCATCCCAG
SOX-9 MUTANT : CAAAGGTACTATAACAGGAAACCATCCCAG
59 ETV MUTANT : AACTAACAATAACAGGAAACCATCCCAG
39 ETV MUTANT : CAAAGGAACAATAACAGGCTACCATCCCAG
59&39 ETV MUTANT : AACTAACAATAACAGGCTACCATCCCAG
ALL MUTANT : AACTTACTATAACAGGCTACCATCCCAG
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1.5610
5cells/ml in Matrigel, control cells formed grape-like
clusters after 9 days (Fig. 1C, left). In contrast, cells growing in
Matrigel and treated with concentrations of 9-cis-RA less
than10
27 M, often exhibited sinus-like structures (Fig. 1C, middle
and right). Cells treated with 10
29 M9 - cis-RA for 9 days formed
colonies of fused cells with sinus-like structures (Fig. 1C, middle).
The cytoplasmic extensions seen at day 11 contained live cells as
indicated by calcein staining (Fig. 1C, right, inset). When pre-
treated for 24 h with 10
27 M9 - cis-RA and grown at a density of
0.5–1610
6cells/ml SKBR3 cells formed extensive network
structures in Matrigel (Figure 2).
Microarray analysis revealed that many ‘‘endothelial’’ genes were
induced by 9-cis-RA in SKBR-3 cells. Principal component analysis
illustrated the excellent reproducibility of our microarray data (Fig.
S1A). Table 1 shows selected ‘‘endothelial-specific’’ genes that were
up-regulatedby9-cis-RA.TheseincludedCox-1,etsfamilymember
ER81, VE-cadherin, tissue factor pathway inhibitor 2 and E-
selectin.Thesedata indicatedthatthe‘‘epithelial’’differentiationwe
observed in our earlier studies is more likely an ‘‘endothelial-like’’
differentiation [14]. However not all endothelial genes are regulated
by RA, for example neither von Willebrands factor nor N-cadherin
were induced by RA (not shown). Real-time PCR analysis
demonstrated that 9-cis-RA treatment induced VE-cadherin
Figure 1. Morphological changes in SKBR-3 cells induced by 9-cis-RA treatment. (A) Phalloidin staining. Untreated SKBR-3 cells exhibited
cuboidal shape. After 48 h treatment with 9-cis-RA (1 mM), SKBR-3 cells became flattened, enlarged and showed increased cell-cell adhesion, and
often extended a rim of cytoplasm to form lumen-like structures. (B) Electron Microscopy. SKBR-3 cells treated with 9-cis-RA showed cell-cell junctions
(black arrow) and lumens (white arrow), while untreated cells did not form these structures. (C) Matrigel assays at 1.5610
5cells/ml. Control SKBR-3
cells (left), SKBR-3 cells treated with 10
29 M9 - cis-RA for 9 days (middle) and at day 11 (right). Green image in Inset indicates calcein staining.
doi:10.1371/journal.pone.0002714.g001
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breast cancer cell lines (Fig. S1B). Other genes, such as Sox-4, Sox-
18 and Sox-9, which are not known to be associated with
endothelial differentiation, were also reproducibly elevated follow-
ing 48 h of RA treatment (Table 1).
9-cis-RA treatment resulted in a rapid and sustained
increase in VE-cadherin expression in SKBR-3 cells
Among the many endothelial genes identified by microarray
analysis, VE-cadherin is known to play a major role in
angiogenesis [15]. Using real-time PCR, we confirmed that the
level of VE-cadherin transcripts was increased in response to 9-cis-
RA (Fig. 3A). Steady state levels of VE-cadherin transcripts were
significantly elevated within 2 h of 9-cis-RA treatment (6.84 fold),
and were sustained for at least 120 h (maximum 116 fold). We also
examined the time- and dose-dependent effects of 9-cis-RA on VE-
cadherin protein (Fig. 3A, inset). Robust induction of VE-cadherin
protein was detected at 24 h after treatment with 9-cis-RA. In
addition, concentrations as low as 10
29 M9 - cis-RA resulted in
significant increases in VE-cadherin protein after 48 h, indicating
that 9-cis-RA is able to induce VE-cadherin in SKBR-3 cells at
levels below the physiological concentration (10
28 M). Immuno-
staining analysis also confirmed that 9-cis-RA induces endogenous
VE-cadherin which is primarily localized at the cell membrane,
resulting in cell-cell adhesion in SKBR-3 cells (Fig. 3A, right).
9-cis-RA rapidly and significantly induced Sox-9 and ER81
Our in silico studies indicated that VE-cadherin may not be a
direct target of RA, since we were unable to find retinoic acid
response elements (RAREs) in the human VE-cadherin promoter.
Therefore, we hypothesized that the effects of RA on VE-cadherin
expression are mediated by RA induction of other, perhaps
known, endothelial regulatory genes. VE-cadherin expression is
known to be regulated by members of the ets family of
transcription factors [16,17]. Indeed, our examination of the
VE-cadherin promoter suggested ets and sox binding sites in VE-
cadherin promoter. We reasoned that any candidate mediator
genes for VE-cadherin expression would be also rapidly induced
by 9-cis-RA in SKBR-3 cells. Sox-9, a member of the high
mobility group (HMG) box gene family of transcription factors,
was one of the candidate genes identified in our microarray.
Indeed, Sox-9 is known as a target of RA. In the Sox-9 promoter,
there are three potential RARE sites at 500 bp upstream from the
transcription initiation site [18]. Another candidate gene was
ER81 (ETV1; ets variant gene1). The ER81 promoter contains 4
RARE sites, and RA induces Ets1 transcription. Using real-time
PCR analysis We found that he Sox-9 transcript was rapidly
elevated by 9-cis-RA-treatment (Fig. 3B, left), and was increased
8.28 fold after 2 h exposure to 9-cis-RA. Significant induction of
Sox-9 protein was also observed, and it preceded the expression of
VE-cadherin (Fig. 3B, left inset). Induction of Sox-4 and Sox-18 by
9-cis-RA were also observed, but levels did not begin to increase
until well after VE-cadherin induction (not shown). Increase of
nuclear expression of Sox-9 by 9-cis-RA was also observed by
immunostaining (Fig. 3B right). Similarly, we confirmed that the
transcript of ER81 increased more than two fold following 2 h of
9-cis-RA treatment (Fig. 3C). Likewise, 9-cis-RA-induction of Cox-
Figure 2. 9-cis-RA induces SKBR3 cells to form networks in Matrigel. Matrigel assays at 1610
6cells/ml. (A) SKBR3 cells grown in Matrigel for
48 h. (B) SKBR3 cells pretreated for 24 h with 10
27M RA and grown in Matrigel for 48 h.
doi:10.1371/journal.pone.0002714.g002
Table 1. Endothelial genes significantly (p,0.01) induced by
9-cis RA in SKBR-3 cells.
Gene Name
Gene ID#
(Entrez
Gene)
Accession #
(GenBank)
Fold
induction
Prostaglandin endoperoxide
synthase 1 (Cox-1)
5742 M59979.1 16
ETS variant gene 1 (ETV1; ER81) 2115 NM_004956.3 11.8
Tissue factor pathway inhibitor-2 7980 L27624.1 11.9
VE-cadherin (cadherin-5) 1003 X79981.1 11.4
E-selectin 6401 M30640.1 10.5
Lipocalin 3933 NM_002297.2 5.9
Bradykinin receptor B2 624 S56772.1 5.5
Sox-18* 54345 AB033888.1 5.4
Fibrinogen beta chain 2244 NM_005141.2 3.9
Sox-4* 6659 AF070669.1 3.6
Ets-like factor 5 2001 AF049703.1 3
Sox-9* 6662 S74506.1 3
Fibrinogen gamma chain 2266 NM_021870.2 2.8
Endothelin converting enzyme 1889 D49471.1 2.6
Endothelin-2 1907 M65199.1 2.4
Vascular endothelial growth
factor D (VEGF-D)
2277 AJ000185.1 1.8
Endothelial differentiation
G-protein coupled receptor
1901 M31210.1 1.7
Endothelial PAS domain protein 2034 U81984.1 1.7
*sox genes not endothelial specific.
doi:10.1371/journal.pone.0002714.t001
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transcriptase-PCR (Fig. 3C inset).
Sox-9 and ER81 were both necessary for 9-cis-RA-
mediated VE-cadherin expression, but neither was
sufficient to induce VE-cadherin in SKBR-3 cells
Because Sox-9 was rapidly induced by 9-cis-RA (Fig. 3B) and the
VE-cadherin promoter contains a well-conserved Sox-9 binding
site, we considered Sox-9 as a candidate to co-operate with ER81 in
thetranscriptionalregulationofVE-cadherin. Sox-9isnotknownto
be involved in endothelial differentiation, but is an important
determinant of the chondrocyte lineage [19]. We next tested
whether Sox-9 and ER81 mediate 9-cis-RA-induced VE-cadherin
expression in the SKBR-3 cells. When cells were transiently
transfected with DN-FLAG-Sox-9 lacking the C-terminal trans-
activation domain, VE-cadherinexpression wasnot observed in any
transfected cells in the presence of 9-cis-RA (Fig. 4A, indicated by
arrows). Efficiency of plasmid DNA transfection in SKBR-3 cells
was 30–50% using Amaxa electroporation. Consistent with this,
DN-FLAG-Sox-9 reduced 9-cis-RA-mediated induction of VE-
cadherinbyapproximately50%asjudgedbyWesternblot(Fig.4B).
These data suggest that Sox-9 positively mediates 9-cis-RA-induced
VE-cadherin expression in SKBR-3 cells.
Ets transcription factors are known to be involved in
angiogenesis [20]. There are Ets binding sites in the VE-cadherin
promoter, and Ets1 has can positively regulate VE-cadherin
transcription in endothelial cells [16,21,22]. Consistent with these
studies, we observed that cells transfected with a DN form of
ER81, lacking the N-terminal trans-activation domain, clearly
lacked membrane staining of VE-cadherin (Fig. 4C).
Next we examined whether Sox-9 and ER81 are sufficient to
induce VE-cadherin expression in the absence of 9-cis-RA. As
shown in Fig. 4D, expression of WT-Sox-9, WT-ER81 or both
failed to induce the expression of VE-cadherin. Taken together,
these results suggested that both Sox-9 and ER81 are required for
Figure 3. 9-cis-RA induced VE-cadherin, Sox-9 and ER81
expression. (A) VE-cadherin induction by 9-cis-RA. Bar graph indicates
VE-cadherin real-time PCR in SKBR-3 cells treated with 9-cis-RA (1 mM)
for indicated times. Insets are Western blots showing time (upper)- and
dose (lower)- dependence of 9-cis-RA on VE-cadherin protein expres-
sion. GAPDH was used as a loading control. Right panel shows 9-cis-RA
(0.1 mM) induced expression and the membrane localization of VE-
cadherin (green) in SKBR-3 cells after 48 h treatment. Blue staining
represents nuclei stained with DAPI. (B) Sox-9 induction by 9-cis-RA. Bar
graph indicates Sox-9 real-time PCR. Inset shows time-dependent
induction of Sox-9 protein. Right panel shows immunostaining. 9-cis-
RA-induced Sox-9 (red) was localized at nuclei in SKBR-3 cells. (C) ER81
induction by 9-cis-RA. Bar graph indicates ER81 real-time PCR. (D)
Reverse transcriptase-PCR showing induction of E-selectin and Cox-1 by
9-cis-RA (0.1 mM, 48 h). b-actin was used as an internal control. All of
these data is representative result of more than three independent
experiments.
doi:10.1371/journal.pone.0002714.g003
Figure 4. Sox-9 and ER81 were necessary for RA-mediated VE-
cadherin expression, but not sufficient to induce VE-cadherin.
(A) VE-cadherin expression lacked in SKBR-3 cells expressing DN form of
Sox-9. SKBR-3 cells were transfected with FLAG-Sox-9 DN by Amaxa
transfection, and treated with 9-cis-RA (0.1 mM). After 48 h, cells were
fixed and double-stained with anti-FLAG (red) and anti-VE-cadherin
(green) antibodies. The pictures show representative result from
multiple experimental samples. (B) Western blot analysis. RA-induced
VE-cadherin expression was partially inhibited by FLAG-Sox-9 DN. (C)
VE-cadherin expression lacked in SKBR-3 cells expressing DN form of
ER81. SKBR-3 cells were transfected with 6xMyc-ER81 DN by Amaxa
transfection. Cells were stained with anti-Myc (red), anti-VE-cadherin
(green) antibodies and DAPI (blue). The pictures show representative
result from multiple experimental samples. (D) The effect of transient
transfection of FLAG-Sox-9 WT and 6xMyc-ER81 WT in SKBR-3 cells. VE-
cadherin expression was not induced by FLAG-Sox-9 WT or Myc-ER81
WT when expressed independently or together. Data is representative
of three independent experiments.
doi:10.1371/journal.pone.0002714.g004
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however, they are not sufficient to induce VE-cadherin protein in
the absence of 9-cis-RA.
Sox-9 and ER81 bound to the VE-cadherin promoter in
response to 9-cis-RA
Sequences between 2166 bp and 25 bp are critical for human
VE-cadherin promoter activity in endothelial cells [16]. Our
analysis revealed that the human VE-cadherin promoter has one
Sox-9 binding site (59-AACAAT-39) and two ETV binding sites (59-
GGAA-39) located between 2114 bp and 286 bp (Fig. 5A). For
convenience, we named these two ETV binding sites as 59 ETV site
and 39 ETV site, which corresponds to EBS5 and EBS4,
respectively, reported in previous studies [16,22]. Using a wild
type,
32P-labeled probe, two major DNA/protein complexes
formation was observed (Fig. 5B left). Formation of these two
complexes was enhanced by 9-cis-RA (lane 2 and 3, Fig. 5B). 59
ETV mutant probe did not block the complex formation (lane 2/3
and lane 14/15). Sox-9mutant aloneslightly decreased the complex
formation (lane 2/3 vs lane 4/5), and Sox-9 and 39ETV double
mutant failed to form the complex (lane 6/7). The effect of the
double mutant was more significant compared with 39ETV mutant
alone (lane 8/9), suggesting that Sox-9 is also involved in complex
formation. Thus, the Sox-9 site and the 39 ETV site, but not the 59
ETV site, appeared to be involved in complex formation. This
finding was consistent with previous reports showing that the 39
ETV site (EBS4) is essential for ets transcription factors to induce
VE-cadherin in endothelial cells [16,22].
With the 59ETV/39ETV double mutant probe, the two
complexes were still observed (Fig. 5C, left, lane 2, 3). Complex
formation was completely blocked by WT cold oligo (lane 4) but not
Sox-9 mutant cold oligo (lane 5), suggesting that Sox-9 binding is
involved in complex formation. Furthermore, DNA/protein
complex formation induced by RA (Fig. 5C, right) was significantly
inhibited by Sox-9 antibody (lane 3), not by rabbit IgG control (lane
4). These results indicated that Sox-9 is involved in the DNA/
protein complex induced by 9-cis-RA in SKBR-3 cells.
Complex formation was often enhanced with the 59 ETV mutant
probe compared with WT probe (Fig. 5D; compare lane 1, and 2
and 7, 8). Complex formation induced by 59 ETV mutant probe
was significantly inhibited by ER81 antibody (Fig. 5D, compare
lane 8 and 10). In addition, when both Sox-9 and ER81 antibodies
were combined, the band intensity was significantly decreased
(compare lane 8 and 11). The reason the 59 ETV mutant probe
enhances complex formation is not clear; however, it is possible that
the 59 ETV site might be occupied by another ets family member
protein (s) which is not recognized by the ER81 antibody, therefore
the blocking effect of the ER81 antibody was less significant when
WT oligo probe was used (compare lane 2 and 4). Taken together,
these data indicated that both Sox-9 and ER81 (at the 39ETV site)
directly bind to the VE-cadherin promoter.
VE-cadherin antibody and VE-cadherin siRNA inhibited 9-
cis-RA-induced morphological changes
VE-cadherin is endothelial-specific, a major constituent of the
adherens junctions, is able to protect endothelial cells from
apoptosis and contributes to contact inhibition [23]. Next, we
asked whether VE-cadherin plays an essential role in RA-mediated
endothelial morphological changes in SKBR-3 cells. Treatment
with VE-cadherin antibody raised against extracellular domain of
VE-cadherin completely reversed the 9-cis-RA-induced morpho-
logical changes, including the formation of lumen and sinus-like
structures (Fig. 6A), suggesting that homotypic interaction of VE-
cadherins at the cell membrane contributes to the 9-cis-RA-
induced cell-cell adhesion and endothelial morphological changes.
We next examined the effect of VE-cadherin knockdown on 9-cis-
RA-induced cell shape changes. Using pooled siRNA, we were
able to obtain almost complete knockdown of endogenous VE-
cadherin (Fig. 6B and 6C). 9-cis-RA-induced morphological
changes were blocked in cells transfected with VE-cadherin
siRNA (Fig. 6C compare middle and right panel). Thus, VE-
cadherin is essential in 9-cis-RA-induced morphological alteration
in SKBR-3 cells.
Exogenous expression of VE-cadherin partially
recapitulated 9-cis-RA-dependent morphological
changes
We next examined if VE-cadherin expression is sufficient to
reproduce the effect of 9-cis-RA in phenotypic changes. Human
VE-cadherin was transiently tranfected into SKBR-3 cells
(Fig. 6D). SKBR-3 cells expressing VE-cadherin showed promi-
nent cell-cell adhesion (Fig. 6D, middle, asterisk) and flattened
(Fig. 6D right, asterisk). However, this morphological change was
not identical to that induced by 9-cis-RA as VE-cadherin
expressing cells did not exhibit the cytoplasmic extensions
observed following treatment with 9-cis-RA (Fig. 6C, left, arrow).
These data indicated that VE-cadherin expression can partially,
but not completely, reproduce endothelial-like phenotypic changes
induced by 9-cis-RA in SKBR-3 cells.
SKBR3 cells form mixed networks with human umbilical
vein endothelial cells
Although SKBR3 cells cannot form tumors in nude mice we did
find that RA-treated SKBR3 cells could form mixed vessel-like
structures when co-cultured with human umbilical vein endothe-
lial cells (HUVECs). In the absence of RA SKBR3 cells decorated
the surface of HUVEC networks but did not fuse or actually
become part of the network (Fig. 7A). Remarkably in the presence
of RA, SKBR3 cells formed nodes from which the HUVECs
either grew toward or emanated from (Figure 7B).
Discussion
Growth, proliferation and metastasis of most tumors is
dependent on adequate vasculature [24]. ‘‘Vasculogenic mimicry’’
is a concept that illustrates the plasticity of tumor cells, their ability
to contribute to vasculogenic-like networks and the expression of
genes associated with multiple cellular phenotypes. There is a
growing body of in vivo evidence that tumor cells can line channels,
sinuses and vessel-like spaces. In addition, mosaic blood vessels
occur in colon carcinomas and melanomas. The formation of
these networks seems to recapitulate the embryonic development
of vasculogenic networks, and is associated with the distinctly
patterned, extra-cellular matrix-rich networks that are observed in
aggressive tumors. In aggressive melanoma with a vasculogenic
phenotype, altered expression of angiogenesis/vasculogenesis-
related genes such as VE-cadherin, E-selectin and tissue-factor
pathway inhibitor is observed [3]. We show that 9-cis-RA induced
these endothelial specific genes in SKBR-3 breast cancer cells with
concomitant endothelial-like morphological alterations including
network formation in Matrigel. SKBR3 cells cannot form tumors
when explanted in nude mice so we cannot directly test if the
endothelial transdifferentiation we observe influences their tumor
growth. However we do find that RA-treated SKBR3 cells can
form mixed vessel-like structures when co-cultured with HUVECs.
These findings suggest that, under certain circumstances, RA
treatment triggers an endothelial-like transdifferentiation in a
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PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2714Figure 5. Sox-9 and ER81 bound to the human VE-cadherin promoter. (A) Sox-9 (59-AACAAT-39) and two ER81 (59-GGAA-39) binding sites
were present between 2114 bp and 286 bp in the human VE-cadherin gene. (B) EMSA with various
32P-labeled probes. With wild type probe, two
major bands (arrows) were detected, and the formation of these complexes was increased by 9-cis-RA (1 mM). Complex formation was diminished by
mutation of the Sox-9 binding site and 39 ETV binding site but was not affected by mutation in the 59 ETV binding site. (C) Sox-9 binds to VE-cadherin
promoter: (left) competition experiment with cold WT and Sox-9 mutant probes. (right) effect of Sox-9 antibody on 9-cis-RA-induced DNA/protein
complex formation. (D) Both Sox-9 and ER81 antibodies inhibited 9-cis-RA-dependent complex formation. WT probe and 59-ETV mutant probe were
used and compared. Note that 59-ETV probe showed enhanced DNA/protein complex formation, which was reduced by either, Sox-9 antibody, ER81
antibody, and their combination. Data is representative of three independent experiments.
doi:10.1371/journal.pone.0002714.g005
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mixed vessels with the host vasculature resulting in an unfavorable
clinical outcome.
VE-cadherin is exclusively expressed in endothelial cells and is
restricted to cell-to-cell junctions where it mediates cell adhesion.
Using VE-cadherin null embryonicbodyand mouse model systems,
it was shown that VE-cadherin plays an essential role in
angiogenesis duringdevelopment[25,26]. In addition,VE-cadherin
has been implicated in tumorigenesis in the adult, and monoclonal
antibodies against VE-cadherin prevent angiogenesis, suggesting
that VE-cadherin is a potential target in cancer treatment [27,28].
Our antibody blockade and siRNA experiments also showed that
VE-cadherin plays a central role in RA-induced morphological
changes. However, the extent to which VE-cadherin directly
induces an endothelial genetic program remains elusive.
The effect of RA in the present study is reminiscent of the effects
of RA in driving differentiation during development [29,30]. In
these situations, master regulatory genes, such as those in the
homeobox, sox and ets families are targets for RA through RARE
elements in their promoters, and these genes ultimately result in
RA-induced changes in cell fate. Sox-9 plays an essential role in
sex determination downstream of the sex-determining region Y
(SRY) in mammals [31,32]. In addition, Sox-9 directly regulates
Col2a1, the gene encoding type II collagen , and serves as a master
regulatory gene in chondrocyte differentiation [19,33] [34,35].
Although no previous studies have shown a role for Sox-9 in
regulating VE-cadherin expression and endothelial trans-differen-
tiation, expression of Sox-9 is detected in the developing mouse
heart [36,37], and Sox-9 null mice are embryonic lethal exhibiting
major cardiovascular abnormalities [38]. These studies suggest
that in addition to its role in sex determination and chondrogen-
esis, Sox-9 may play a broader role in the cardiovascular system.
Given that VE-cadherin is widely expressed in the developing
heart and vascular system , it is possible that Sox-9 is implicated in
VE-cadherin expression during embryonic development [39].
Consistent with this, Sox-9 regulates the epithelial-mesenchymal
transition and proliferation in endocardial cells that precedes the
development of the heart valves [38].
Our data demonstrated that SKBR-3 cells treated with RA turned
on an endothelial-like genetic program and acquired some
phenotypic characteristics of endothelial cells such as sinus formation,
lumen-like structures and the ability to form networks in Matrigel. It
is possible that angiogenesis is secondary to vasculogenesis in
providing a circulatory system for the growing tumor. In other
words, RA-induced trans-differentiated cells may provide a homing
mechanism for circulating endothelial cells (CECs) or bone marrow-
derived endothelial precursor cells (EPCs). Circulating endothelial
cells and progenitor cells are clearly important in tumor growth [40].
Thus, it is possible that these CECs/EPCs migrate to the tumor site
and are stabilized at that location because of homotypic cell-cell
interactions between cell surface antigens (e.g. VE-cadherin) that are
common to both trans-differentiated tumor cells and migrating
CECs/EPCs. The observations that RA-treated SKBR3 cells formed
nodes form which HUVEC networks appear to nucleate is consistent
with this possibility.
The ability of carcinoma cells to take on characteristics typical of
cellsfromquite different backgrounds iswell established and maybe
related to a stem cell-like origin. Perhaps the best example of this is
the ability of breast carcinoma cells to acquire the molecular and
phenotypic hallmarks of migratory and invasive mesenchymal cells
[41,42]. Our data suggests that these properties need to be taken
into account when considering treatment or prevention regimens
using potent differentiating agents such as vitamins A and D.
Although some agents might inhibit proliferation ofa subpopulation
of tumor cells, they might stimulate the trans-differentiation of
another subpopulation. Clearly, those tumor cells that re-acquire
differentiated properties in response to such an agent still harbor the
genetic defects that transformed them initially and cannot be
considered as normal differentiated cells.
In summary, we demonstrated that 9-cis-RA induces endothe-
lial-like trans-differentiation in SKBR-3 cells. These phenotypic
changes are accompanied by significant induction of the
endothelial genetic program. VE-cadherin plays a central role in
these morphological alterations, and we found that both Sox-9 and
ER81 bind to VE-cadherin promoter and participate in its
Figure 6. VE-cadherin played an essential role in 9-cis-RA-
mediated morphological changes. (A) Antibody neutralization
experiment. Morphology of SKBR-3 cells was visualized by phalloidin
staining. (B) The effect of VE-cadherin siRNA in SKBR-3 cells. Cells were
tranfected with VE-cadherin siRNA using Amaxa transfection procedure,
and incubated for 6 h followed by additional 48 h incubation in the
presence or absence of RA (0.1 mM). (C) The effect of VE-cadherin
suppression in SKBR-3 cell shape. VE-cadherin siRNA completely
blocked 9-cis-RA-mediated VE-cadherin expression (green) and locali-
zation to the cell surface (upper series). Phalloidin staining (red)
indicated that 9-cis-RA-dependent, flattened morphology, cell-cell
adhesion and cytoplasmic extensions were blocked by VE-cadherin
siRNA (Lower series). (D) The effect of VE-cadherin transfection on cell
morphology. SKBR-3 cells were transiently tranfected with human VE-
cadherin using Amaxa system and analyzed 48 h after transfection. VE-
cadherin expressing cells (green) were flattened (asterisk) and had more
prominent cell-cell adhesion compared with non-VE-cadherin express-
ing cells. However, VE-cadherin expression did not stimulate the
formation of cytoplasmic extension structures induced by RA (arrow).
These data are representative of three independent experiments.
doi:10.1371/journal.pone.0002714.g006
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mixed results of clinical trials using various vitamin A analogues,
and bring up the rather disturbing notion that treatments with
retinoids might stimulate certain tumor cells to acquire vasculo-
genic properties.
Supporting Information
Figure S1 Microarray and q-PCR analyses.
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